Amol Akhade: Lurbinectedin and Atezolizumab show significant benefits in ES-SCLC maintainence

Amol Akhade shared a post on X:

“Lurbinectedin plus Atezo shows Both PFS and OS benifit against atezolizumab maintenance in ES-SCLC after atezolizumab plus chemo in first line in IMforte trial.

It will be intresting to see magnitude of benifit for addition of Lurbinectedin in first line setting.”

Additional information

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.